$0.03
−17.29%Price chart
Sep 17Sep 22Sep 25Sep 30Oct 5Oct 8Oct 14Oct 19
Key dataOct 19, 2026
Open$0.03
From 52W high−95.77%
Volume8944.00
Market cap$150293.85
P/E (TTM)—
P/S (TTM)11.1x
Div yield—
Key dataOct 19, 2026
Open
$0.03
From 52W high
−95.77%
Volume
8944.00
Market cap
$150293.85
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−1.4x
P/E (TTM)
—
RSI (14)
38.6
MomentumView details →
1D Return
−17.29%
YTD Return
−73.17%
SummaryUpdated Jun 1, 2026
Ainos, Inc. (NASDAQ:AIMD) is a biotechnology company founded in 1984 and headquartered in San Diego, California. Originally incorporated as Amarillo Biosciences, Inc., the company rebranded to Ainos in May 2021 and went public through an IPO in January 2021. The company operates in the healthcare sector, focusing on developing medical technologies for point-of-care diagnostic testing and novel therapeutic treatments for various disease indications.
Similar companies
Latest newsMore news →
Ainos, Inc. completed the data delivery and technology transfer under its VELDONA license agreement, triggering a $600,000 initial license payment from its licensing partner.20d agoAinos, Inc. completed delivery of all 1,400 AI Nose systems to ASE Technology Holding Co., Ltd. under a $2.1 million three-year agreement, with revenue expected to begin in third-quarter 2026.21d agoAinos, Inc. entered into a VELDONA license agreement with BioPhoenix Co., Ltd., establishing a collaboration framework with a potential aggregate value of $10 million, under which BioPhoenix will fund and advance clinical and regulatory development for two initial indications.26d ago